To get in touch with us, 

please email our executive officer at

m.coleman@centenary.org.au

  • White Instagram Icon
  • White YouTube Icon
  • White Facebook Icon

©2023 by TB CRE. Proudly created with wix.com

  • Mikaela Coleman

MDR-TB infection and disease in children

TB-CRE Investigator Professor Ben Marais co-authors a review of new and repurposed drugs for treatment of multi-drug resistant TB in children.




The World Health Organization estimates that 10 million new cases of tuberculosis (TB) occurred worldwide in 2017, of which 600,000 were rifampicin or multidrug-resistant (RR/MDR) TB. Modelling estimates suggest that 32,000 new cases of MDR-TB occur in children annually, but only a fraction of these are correctly diagnosed and treated. Accurately diagnosing TB in children, who usually have paucibacillary disease, and implementing effective TB prevention and treatment programs in resource-limited settings remain major challenges. In light of the underappreciated RR/MDR-TB burden in children, and the lack of paediatric data on newer drugs for TB prevention and treatment, the authors present an overview of new and repurposed TB drugs, describing the available evidence for safety and efficacy in children to assist clinical care and decision-making.


Huynh J, Marais BJ. Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs. Ther Adv Infect Dis 2019;6:2049936119864737. doi: 10.1177/2049936119864737.